Company intelligence / Profile preview

InvHealth Holding

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

InvHealth is a clinical-stage biotechnology company dedicated to discovering and developing innovative small molecule therapies for metabolic diseases. The company's lead program, INV-1120, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently being evaluated for the treatment of metabolic-associated steatohepatitis (MASH). InvHealth leverages its expertise in structure-based drug design to create potent and selective candidates that address significant unmet needs in the metabolic and cardiovascular space. Headquartered in Suzhou, China, the company is supported by a team of industry veterans and top-tier venture capital investors.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on InvHealth Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InvHealth Holding.

Explore the full profile